Abstract
The tripeptide glycine-proline-glutamate (GPE) is the naturally cleaved N-terminal tripeptide of insulin-like growth factor-1 (IGF-1) in brain tissues by an acid protease. Although GPE does not bind to IGF-1 receptors and its mode of action is not clear, in vitro studies have demonstrated its ability to stimulate acetylcholine and dopamine release, as well as to protect neurones from diverse induced brain injures. More importantly, GPE has been shown to have potent neuroprotective effects in numerous animal models of hypoxic-ischemic brain injury and neurodegenerative diseases such as Parkinsons, Alzheimers and Huntingtons diseases. As a consequence, GPE was suggested to be a potential target for the rational design of neuroprotective agents. Unfortunately, the use of GPE as a therapeutic agent is limited because of its unfavorable biochemical and pharmacokinetic properties. This review will focus on structural modifications performed on the GPE molecule in order to obtain bioactive analogues with increased pharmacokinetic profile useful for the treatment of central nervous system (CNS) injures and neurodegenerative disorders.
Keywords: Glycine-proline-glutamate, GPE analogues, macrocyclic GPE analogues, structure-activity relationships, neuroprotective agents, neurodegenerative disease, hypoxic-ischemic brain injury, Huntington's diseases, neurodegenerative diseases, Ligand-receptor interactions, amino-terminal glycine, carboxy-teminal glutamate, postoperative period, proline-analogues
Mini-Reviews in Medicinal Chemistry
Title: GPE and GPE Analogues as Promising Neuroprotective Agents
Volume: 12 Issue: 1
Author(s): I. Cacciatore, C. Cornacchia, L. Baldassarre, E. Fornasari, A. Mollica, A. Stefanucci and F. Pinnen
Affiliation:
Keywords: Glycine-proline-glutamate, GPE analogues, macrocyclic GPE analogues, structure-activity relationships, neuroprotective agents, neurodegenerative disease, hypoxic-ischemic brain injury, Huntington's diseases, neurodegenerative diseases, Ligand-receptor interactions, amino-terminal glycine, carboxy-teminal glutamate, postoperative period, proline-analogues
Abstract: The tripeptide glycine-proline-glutamate (GPE) is the naturally cleaved N-terminal tripeptide of insulin-like growth factor-1 (IGF-1) in brain tissues by an acid protease. Although GPE does not bind to IGF-1 receptors and its mode of action is not clear, in vitro studies have demonstrated its ability to stimulate acetylcholine and dopamine release, as well as to protect neurones from diverse induced brain injures. More importantly, GPE has been shown to have potent neuroprotective effects in numerous animal models of hypoxic-ischemic brain injury and neurodegenerative diseases such as Parkinsons, Alzheimers and Huntingtons diseases. As a consequence, GPE was suggested to be a potential target for the rational design of neuroprotective agents. Unfortunately, the use of GPE as a therapeutic agent is limited because of its unfavorable biochemical and pharmacokinetic properties. This review will focus on structural modifications performed on the GPE molecule in order to obtain bioactive analogues with increased pharmacokinetic profile useful for the treatment of central nervous system (CNS) injures and neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Cacciatore I., Cornacchia C., Baldassarre L., Fornasari E., Mollica A., Stefanucci A. and Pinnen F., GPE and GPE Analogues as Promising Neuroprotective Agents, Mini-Reviews in Medicinal Chemistry 2012; 12 (1) . https://dx.doi.org/10.2174/138955712798868995
DOI https://dx.doi.org/10.2174/138955712798868995 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Targeting the p53 Pathway of Apoptosis
Current Pharmaceutical Design The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Age-Dependent Microglial Activation in Immature Brains After Hypoxia- Ischemia
CNS & Neurological Disorders - Drug Targets Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies
Current Pharmaceutical Design The Role of Vascular Endothelial Growth Factor in Neurogenesis in Adult Brain
Mini-Reviews in Medicinal Chemistry Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Hepatocyte Growth Factor and Insulin-like Growth Factor-1 based Cellular Therapies for Oxidative Stress Injury
Current Stem Cell Research & Therapy Ginkgo biloba Extract 761: A Review of Basic Studies and Potential Clinical Use in Psychiatric Disorders
CNS & Neurological Disorders - Drug Targets New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease
Current Vascular Pharmacology Gamma-Oryzanol – A Multi-Purpose Steryl Ferulate
Current Nutrition & Food Science Current Status and Future Directions of Multimodality Therapy for Non- Small Cell Lung Cancer of the Superior Sulcus
Current Cancer Therapy Reviews A Short Review of Diffusion Models and their Possibilities to Enhance Imaging Biomarkers for Neurodegenerative Diseases
Current Medical Imaging Necessity for Re-Vascularization after Spinal Cord Injury and the Search for Potential Therapeutic Options
Current Neurovascular Research Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease
Current Drug Therapy Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?
Current Drug Targets